Information de reference pour ce titreAccession Number: | 00063043-201511000-00004.
|
Author: | Chan, Philip A. MD 1; Rose, Jennifer PhD 2; Maher, Justine 1; Benben, Stacey 1; Pfeiffer, Kristen 1; Almonte, Alexi 1; Poceta, Joanna 1; Oldenburg, Catherine E. 3; Parker, Sharon PhD 4; Marshall, Brandon DL PhD 5; Lally, Mickey MD 1; Mayer, Kenneth MD 6; Mena, Leandro MD 7; Patel, Rupa MD 8; Nunn, Amy S. ScD 9
|
Institution: | (1) Division of Infectious Diseases, Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island. (2) Department of Psychology, Wesleyan University, Middletown, Connecticut. (3) Department of Epidemiology, Harvard T.H. Chan School of Public Health, Cambridge, Massachusetts. (4) Department of Social Work, North Carolina Agricultural and Technical State University, Greensboro, North Carolina. Departments of (5) Epidemiology and (9) Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island. (6) Fenway Health, The Fenway Institute, Boston, Massachusetts. (7) Division of Infectious Diseases, University of Mississippi Medical Center, Jackson, Mississippi. (8) Division of Infectious Diseases, Washington University in St. Louis School of Medicine, St. Louis, Missouri.
|
Title: | A Latent Class Analysis of Risk Factors for Acquiring HIV Among Men Who Have Sex with Men: Implications for Implementing Pre-Exposure Prophylaxis Programs.[Miscellaneous]
|
Source: | AIDS Patient Care & Stds. 29(11):597-605, November 2015.
|
Abstract: | Current Centers for Disease Control and Prevention (CDC) guidelines for prescribing pre-exposure prophylaxis (PrEP) to prevent HIV transmission are broad. In order to better characterize groups who may benefit most from PrEP, we reviewed demographics, behaviors, and clinical outcomes for individuals presenting to a publicly-funded sexually transmitted diseases (STD) clinic in Providence, Rhode Island, from 2012 to 2014. Latent class analysis (LCA) was used to identify subgroups of men who have sex with men (MSM) at highest risk for contracting HIV. A total of 1723 individuals presented for testing (75% male; 31% MSM). MSM were more likely to test HIV positive than heterosexual men or women. Among 538 MSM, we identified four latent classes. Class 1 had the highest rates of incarceration (33%), forced sex (24%), but had no HIV infections. Class 2 had <5 anal sex partners in the previous 12 months, the lowest rates of drug/alcohol use during sex and lower HIV prevalence (3%). Class 3 had the highest prevalence of HIV (7%) and other STDs (16%), > 10 anal sex partners in the previous 12 months (69%), anonymous partners (100%), drug/alcohol use during sex (76%), and prior STDs (40%). Class 4 had similar characteristics and HIV prevalence as Class 2. In this population, MSM who may benefit most from PrEP include those who have >10 sexual partners per year, anonymous partners, drug/alcohol use during sex and prior STDs. LCA is a useful tool for identifying clusters of characteristics that may place individuals at higher risk for HIV infection and who may benefit most from PrEP in clinical practice.
(C) 2015 Mary Ann Liebert, Inc
|
References: | 1. Johnson AS, Hall HI, Hu X, et al. Trends in diagnoses of HIV infection in the United States, 2002-2011. JAMA 2014;312: 432-434.
2. Mayer KH, Venkatesh KK. Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol 2011;65:308-316.
3. Piot P, Laga M. Genital ulcers, other sexually transmitted diseases, and the sexual transmission of HIV. BMJ 1989;298:623-624.
4. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999;75:3-17.
5. Sexton J, Garnett G, Rottingen JA. Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis 2005;32:351-357.
6. United States Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection, 2012.
7. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
8. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
9. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367: 423-434.
10. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083-2090.
11. Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: Where have we been and where are we going? J Acquir Immune Defic Syndr 2013;63:S122-S129.
12. Liu A, Cohen S, Follansbee S, et al. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med 2014;11:e1001613.
13. Centers for Disease Control and Prevention. Pre-exposure prophylaxis for the prevention of HIV infection in the United States-2014 Clinical Practice Guideline, 2014.
14. Smith DK, Pals SL, Herbst JH, et al. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr 2012;60:421-427.
15. LaLota M, Beck DW, Metsch LR, et al. HIV seropositivity and correlates of infection among heterosexually active adults in high-risk areas in South Florida. AIDS Behav 2011;15:1259-1263.
16. Jenness SM, Neaigus A, Murrill CS, et al. Estimated HIV incidence among high-risk heterosexuals in New York City, 2007. J Acquir Immune Defic Syndr 2011;56:193-197.
17. Menza TW, Hughes JP, Celum CL, Golden MR. Prediction of HIV acquisition among men who have sex with men. Sex Transm Dis 2009;36:547-555.
18. Monga N, Rehm J, Fischer B, et al. Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. Drug Alcohol Depend 2007;88:1-8.
19. Reboussin BA, Song EY, Shrestha A, et al. A latent class analysis of underage problem drinking: Evidence from a community sample of 16-20 year olds. Drug Alcohol Depend 2006;83:199-209.
20. Agrawal A, Lynskey MT, Madden PA, et al. A latent class analysis of illicit drug abuse/dependence: Results from the National Epidemiological Survey on Alcohol and Related Conditions. Addiction 2007;102:94-104.
21. Martins SS, Carlson RG, Alexandre PK, Falck RS. Perceived risk associated with ecstasy use: A latent class analysis approach. Addict Behav 2011;36:551-554.
22. Kuramoto SJ, Bohnert AS, Latkin CA. Understanding subtypes of inner-city drug users with a latent class approach. Drug Alcohol Depend 2011;118:237-243.
23. Hopfer S, Tan X, Wylie JL. A social network-informed latent class analysis of patterns of substance use, sexual behavior, and mental health: Social Network Study III, Winnipeg, Manitoba, Canada. Am J Public Health 2014;104: 834-839.
24. Konda KA, Celentano DD, Kegeles S, et al. Latent class analysis of sexual risk patterns among esquineros (street corner men) a group of heterosexually identified, socially marginalized men in urban coastal Peru. AIDS Behav 2011;15:862-868.
25. McCarty-Caplan D, Jantz I, Swartz J. MSM and drug use: A latent class analysis of drug use and related sexual risk behaviors. AIDS Behav 2014;18:1339-1351.
26. Harrell PT, Mancha BE, Petras H, et al. Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors. Drug Alcohol Depend 2012;122:220-227.
27. Bastard M, Fall MB, Laniece I, et al. Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis. J Acquir Immune Defic Syndr 2011;57:55-61.
28. Keiser O, Spycher B, Rauch A, et al. Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: Latent class analysis. AIDS Behav 2012;16:245-255.
29. Pharris A, Hoa NP, Tishelman C, et al. Community patterns of stigma towards persons living with HIV: A population-based latent class analysis from rural Vietnam. BMC Public Health 2011;11:705.
30. Wilkerson JM, Smolenski DJ, Horvath KJ, et al. Online and offline sexual health-seeking patterns of HIV-negative men who have sex with men. AIDS Behav 2010;14:1362-1370.
31. Lanza ST, Kugler KC, Mathur C. Differential effects for sexual risk behavior: An application of finite mixture regression. Open Fam Stud J 2011;4:81-88.
32. Azarsfeld PF, Henry NW. Latent Structure Analysis. Boston: Houghton Mifflin, 1968.
33. McCutcheon AL. Latent Class Analysis. Newbury Park: SAGE Publications, Inc, 1987.
34. McLachlan G, Peel D. Finite Mixture Models. Los Angeles: Wiley, 2000.
35. Celeux G, Soromenho G. An entropy criterion for assessing the number of clusters in a mixture model. J Classific 1996;3:195.
36. Drabkin AS, Sikkema KJ, Wilson PA, et al. Risk patterns preceding diagnosis among newly HIV-diagnosed men who have sex with men in New York City. AIDS Patient Care STDS 2013;27:333-341.
37. Wejnert C, Le B, Rose CE, et al. HIV infection and awareness among men who have sex with men-20 cities, United States, 2008 and 2011. PLoS One 2013;8:e76878.
38. Edwards JM, Iritani BJ, Hallfors DD. Prevalence and correlates of exchanging sex for drugs or money among adolescents in the United States. Sex Transm Infect 2006;82:354-358.
39. Astemborski J, Vlahov D, Warren D, et al. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. Am J Public Health 1994;84: 382-387.
40. Spaulding A, Stephenson B, Macalino G, et al. Human immunodeficiency virus in correctional facilities: A review. Clin Infect Dis 2002;35:305-312.
41. Stockman JK, Lucea MB, Campbell JC. Forced sexual initiation, sexual intimate partner violence and HIV risk in women: A global review of the literature. AIDS Behav 2013; 17:832-847.
42. Centers for Disease Control and Prevention. Routine jailbased HIV testing-Rhode Island, 2000-2007. 2010;742.
43. Rich JD, Hogan JW, Wolf F, et al. Lower syringe sharing and re-use after syringe legalization in Rhode Island. Drug Alcohol Depend 2007;89:292-297.
44. McGowan JP, Shah SS, Ganea CE, et al. Risk behavior for transmission of human immunodeficiency virus (HIV) among HIV-seropositive individuals in an urban setting. Clin Infect Dis 2004;38:122-127.
45. Ostrow DG, Plankey MW, Cox C, et al. Specific sex drug combinations contribute to the majority of recent HIV seroconversions among MSM in the MACS. J Acquir Immune Defic Syndr 2009;51:349-355.
46. Ackers ML, Greenberg AE, Lin CY, et al. High and persistent HIV seroincidence in men who have sex with men across 47 U.S. cities. PLoS One 2012;7:e34972.
47. Rosenberg ES, Millett GA, Sullivan PS, et al. Understanding the HIV disparities between black and white men who have sex with men in the USA using the HIV care continuum: A modeling study. Lancet HIV 2014;1:e112-e118.
48. Millett GA, Peterson JL, Flores SA, et al. Comparisons of disparities and risks of HIV infection in black and other men who have sex with men in Canada, UK, and USA: A meta-analysis. Lancet 2012;380:341-348.
|
Language: | English.
|
Document Type: | CLINICAL AND EPIDEMIOLOGIC RESEARCH.
|
Journal Subset: | Clinical Medicine. Public Health.
|
ISSN: | 1087-2914
|
NLM Journal Code: | 9607225, ckd
|
DOI Number: | https://dx.doi.org/10.1089/apc.2...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|